Co-Diagnostics (NASDAQ:CODX – Get Free Report) and NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Valuation and Earnings
This table compares Co-Diagnostics and NeuroOne Medical Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Co-Diagnostics | $620,000.00 | 33.51 | -$46.90 million | ($15.77) | -0.36 |
| NeuroOne Medical Technologies | $12.10 million | 2.45 | -$3.61 million | ($0.85) | -4.05 |
Profitability
This table compares Co-Diagnostics and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Co-Diagnostics | -6,760.63% | -164.92% | -141.15% |
| NeuroOne Medical Technologies | -68.35% | -98.33% | -69.85% |
Risk and Volatility
Co-Diagnostics has a beta of 2.74, indicating that its share price is 174% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Insider and Institutional Ownership
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 5.4% of Co-Diagnostics shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Co-Diagnostics and NeuroOne Medical Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Co-Diagnostics | 1 | 2 | 1 | 0 | 2.00 |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
Co-Diagnostics presently has a consensus target price of $67.50, indicating a potential upside of 1,098.93%. NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 239.15%. Given Co-Diagnostics’ higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than NeuroOne Medical Technologies.
Summary
NeuroOne Medical Technologies beats Co-Diagnostics on 10 of the 14 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
